Follow-up study after haploidentical transplant in Fanconi anemia
Treatments studied
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows people with Fanconi anemia (a bone marrow failure condition) who receive a transplant from a half-matched (haploidentical) donor. It aims to better understand outcomes and care needs for patients with severe blood counts and higher-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have Fanconi anemia confirmed by a chromosome test and/or genetic testing
- Your age is between 6 months and 60 years
- You have severe low blood counts (for example very low platelets and/or very low white cells, or frequent recent transfusions)
- Your disease is considered high risk due to results like abnormal chromosome patterns, myelodysplastic syndrome, or acute leukemia
- You have a donor who is “haploidentical,” meaning half-matched, and that donor is unaffected
- You can give consent (parents/guardian for minors) and you have social security coverage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a stem cell transplant approach using adjusted chemotherapy doses for people with Fanconi anemia. It may help replace damaged bone marrow and treat blood problems like severe aplastic anemia, MDS, or leukemia.
This trial tests giving a stem cell transplant to a fetus with Fanconi anemia before birth, using the mother's bone marrow cells. The goal is to help the baby's body make healthy blood cells before symptoms start.
This Phase 2 study tests a special “T-cell depleted” transplant plan for people with inherited bone marrow failure disorders (Fanconi anemia or T-Beta-thalassemia—or “TBD”). It may help restore healthy blood production while lowering the chance of certain transplant complications.
This study tests whether a reduced-intensity donor stem cell transplant (with briquilimab as part of the conditioning) can safely treat bone marrow failure in people with Fanconi anemia. It may help by lowering how much intensive treatment is needed before the transplant, while still helping the donor cells grow.
This study looks at how squamous cell carcinoma (a type of cancer) naturally develops over time in people with Fanconi anemia. It may help doctors better recognize warning signs and plan care in the future.
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
Hear when a new Fanconi Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.